Cryptotanshinone inhibits cyclooxygenase-2 enzyme activity but not its expression

European Journal of Pharmacology

Volumn 549, Issue 1-3, 2006, Pages 166-172

  Jin, Dao Zhong ^a   Yin, Lin Lin ^a   Ji, Xin Quan ^a   Zhu, Xing Zu ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Cryptotanshinone; Cyclooxygenase 2; Prostaglandin E2; Reactive oxygen species

Indexed keywords

ARACHIDONIC ACID; CRYPTOTANSHINONE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; INDOMETACIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CATALYSIS; CELL CLONING; CELL STIMULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME MECHANISM; ENZYME RELEASE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INSECT CELL; MONOCYTE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RAT; RNA TRANSLATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACID; BLOTTING, WESTERN; CARRAGEENAN; CELL LINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; EDEMA; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HINDLIMB; HUMANS; MOLECULAR STRUCTURE; PHENANTHRENES; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SALVIA; SPODOPTERA; U937 CELLS;

EID: 33748981088     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.07.055     Document Type: Article

References (33)

1. Barrios-Rodiles M., Keller K., Belley A., and Chadee K. Nonsteroidal antiinflammatory drugs inhibit cyclooxygenase-2 enzyme activity but not mRNA expression in human macrophages. Biochem. Biophys. Res. Commun. 225 (1996) 896-900
2. Basu G.D., Pathangey L.B., Tinder T.L., Gendler S.J., and Mukherjee P. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res. 7 (2005) R422-R435
3. Cao E.H., Liu X.Q., Wang J.J., and Xu N.F. Effect of natural antioxidant tanshinone II-A on DNA damage by lipid peroxidation in liver cells. Free Radic. Biol. Med. 20 (1996) 801-806
4. Cho J.W., Park K., Kweon G.R., Jang B.C., Baek W.K., Suh M.H., Kim C.W., Lee K.S., and Suh S.I. Curcumin inhibits the expression of COX-2 in UVB-irradiated human keratinocytes (HaCaT) by inhibiting activation of AP-1: p38 MAP kinase and JNK as potential upstream targets. Exp. Mol. Med. 37 (2005) 186-192
5. Choi H.S., and Cho D.I. Molecular mechanisms of inhibitory activities of tanshinones on lipopolysaccharide-induced nitric oxide generation in RAW 264.7 cells. Arch. Pharm. Res. 27 (2004) 1233-1237
6. Dean A.K., Bradley S.F., Brian C.V., Robert W.L., and Harvey R.H. TIS 10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 266 (1991) 12866-12872
7. Engblom D., Ek M., Saha S., Ericsson-Dahlstrand A., Jakobsson P.J., and Blomqvist A. Prostaglandins as inflammatory messengers across the blood-brain barrier. J. Mol. Med. 80 (2002) 5-15
8. Gross G.J., and Moore J. Effect of COX-1/COX-2 inhibition versus selective COX-2 inhibition on coronary vasodilator responses to arachidonic acid and acetylcholine. Pharmacology 71 (2004) 135-142
9. Han C., and Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J. Biol. Chem. 280 (2004) 24053-24063
10. Jang S.I., Jeong S.I., Kim K.J., Kim H.J., Yu H.H., Park R., Kim H.M., and You Y.O. Tanshinone IIA from Salvia miltiorrhiza inhibits inducible nitric oxide synthase expression and production of TNF-alpha, IL-1beta and IL-6 in activated RAW 264.7 cells. Plant. Med. 69 (2003) 1057-1059
11. Ji X.Y., Tan B.K., and Zhu Y.Z. Salvia miltiorrhiza and ischemic diseases. Acta. Pharm. Sin. 21 (2000) 1089-1094
12. Kang H.S., Chung H.Y., Jung J.H., Kang S.S., and Choi J.S. Antioxidant effect of Salvia miltiorrhiza. Arch. Pharm. Res. 20 (1997) 496-500
13. Kang B.Y., Chung S.W., Kim S.H., Ryu S.Y., and Kim T.S. Inhibition of interleukin-12 and interferon-gamma production in immune cells by tanshinones from Salvia miltiorrhiza. Immunopharmacology 49 (2000) 355-361
14. Keller A., Mohamed A., Drose S., Brandt U., Fleming I., and Brandes R.P. Analysis of dichlorodihydrofluorescein and dihydrocalcein as probes for the detection of intracellular reactive oxygen species. Free Radic. Res. 38 (2004) 1257-1267
15. Kiefer W., and Dannhardt G. COX-2 inhibition and the control of pain. Curr. Opin. Investig. Drugs 3 (2002) 1348-1358
16. Kim S.Y., Moon T.C., Chang H.W., Son K.H., Kang S.S., and Kim H.P. Effects of tanshinone I isolated from Salvia miltiorrhiza bunge on arachidonic acid metabolism and in vivo inflammatory responses. Phytother. Res. 16 (2002) 616-620
17. McGeer P.L., and McGeer E.G. Inflammation, autotoxicity and Alzheimer disease. Neurobiol. Aging 22 (2001) 799-809
18. Mosaddik M.A. In vitro cytotoxicity of tanshinones isolated from Salvia miltiorrhiza Bunge against P388 lymphocytic leukemia cells. Phytomedicine 10 (2003) 682-685
19. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., Trzaskos J.M., Evans J.F., and Taketo M.M. Suppression of intestinal polyposis in APCD716 knockout mice by inhibition of prostaglandin endoperoxide synthase-2 (COX-2). Cell 87 (1996) 803-809
20. Pagoria D., and Geurtsen W. The effect of N-acetyl-l-cysteine and ascorbic acid on visible-light-irradiated camphorquinone/N,N-dimethyl-p-toluidine-induced oxidative stress in two immortalized cell lines. Biomaterials 26 (2005) 6136-6142
21. Peek Jr. R.M. Prevention of colorectal cancer through the use of COX-2 selective inhibitors. Cancer Chemother. Pharmacol. 54 (2004) 50-56
22. Pronai L., Hritz I., Molnar B., Herszenyi L., and Tulassay Z. COX-2-selective inhibitors (COXIBs): gastrointestinal safety. Int. J. Immunopathol. Pharmacol. 16 (2003) 23-30
23. Rao A.M., Hatcher J.F., and Dempsey R.J. Lipid alterations in transient forebrain ischemia: possible new mechanisms of CDP-choline neuroprotection. J. Neurochem. 75 (2000) 2528-2535
24. Ryu S.Y., Lee C.O., and Choi S.U. In vitro cytotoxicity of tanshinones from Salvia miltiorrhiza. Plant. Med. 63 (1997) 339-342
25. Salvi G.E., and Lang N.P. The effects of non-steroidal anti-inflammatory drugs (selective and non-selective) on the treatment of periodontal diseases. Curr. Pharm. Des. 11 (2005) 1757-1769
26. Sinicrope F.A., and Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev. 23 (2004) 63-75
27. Subbaramaiah K., Telang N., Ramonetti J.T., Araki R., Devito B., Weksker B.B., and Dannenberg A.J. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res. 56 (1996) 4424-4429
28. Sun J., Tan B.K., Huang S.H., Whiteman M., and Zhu Y.Z. Effects of natural products on ischemic heart diseases and cardiovascular system. Acta. Pharm. Sin. 23 (2002) 1142-1151
29. Tacconelli S., Capone M.L., and Patrignani P. Clinical pharmacology of novel selective COX-2 inhibitors. Curr. Pharm. Des. 10 (2004) 589-601
30. Vane J.R., Bakhle Y.S., and Botting R.M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 97-120
31. Wang N., Luo H.W., Niwa M., and Ji J. A new platelet aggregation inhibitor from Salvia miltiorrhiza. Plant. Med. 55 (1989) 390-391
32. Winters M.E., Mehta A.I., Petricoin III E.F., Kohn E.C., and Liotta L.A. Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis. Cancer Res. 65 (2005) 3853-3860
33. Zhang W.Y., Yang X.N., Jin D.Z., and Zhu X.Z. Expression and enzyme activity determination of human cyclooxygenase-1 and-2 in a baculovirus-insect cell system. Acta. Pharm. Sin. 25 (2004) 1000-1006